completion of 10-year-mark studies of the women who already had the breast implants, and the completion of a second, 10-year-mark study of the safety of the breast implants in 40,000 other women. the fda warned the public that breast implants do carry medical risks, and recommended that women who undergo breast augmentation should periodically undergo mri examinations to screen for signs of either shell rupture or of filler leakage, or both conditions; and ordered that breast surgery patients be provided with detailed, informational brochures explaining the medical risks of using silicone-gel breast implants. in march 2019, the fda hosted a public meeting of their general and plastic surgery devices advisory panel to discuss safety issues of silicone and saline breast implants, including bia-alcl and breast implant illness. one of the major topics of that public meeting was the evidence that allergan biocell textured breast implants were the type of breast implants most likely to cause bia-alcl. following the committee meeting, the fda requested that allergan recall their biocell textured breast implants and tissue expanders, and in july 2019 allergan took those biocell textured implants and expanders off the market. allergan subsequently announced they would contact all customers who had purchased their products to ensure they were aware of the recall. the u.s. food and drug administration established the age ranges for women seeking breast implants; for breast reconstruction, silicone-gel filled implants and saline-filled implants were approved for women of all ages; for breast augmentation, saline implants were approved for women 18 years of age and older; silicone implants were approved for women 22 years of age and older. because each breast implant device entails different medical risks, the minimum age of the patient for saline breast implants is different from the minimum age of the patient for silicone breast implants—because of the filler leakage and silent shell-rupture risks; thus, periodic mri screening examinations are the recommended post-operative, follow-up therapy for the patient. in other countries, in europe and oceania, the national health ministries' breast implant policies do not endorse periodic mri screening of asymptomatic patients, but suggest palpation proper—with or without an ultrasonic screening—to be sufficient post-operative therapy for most patients.